LENZ reports Q2 net loss $14.9M; LNZ100 PDUFA on track for Aug 8, 2025

LENZ Therapeutics, Inc.

Cash, cash equivalents and marketable securities $209.6M as of June 30, 2025; >$205M expected by PDUFA date.
Net loss $14.9M ($0.53 per share) for Q2 2025 vs $10.3M ($0.40) in Q2 2024.
NDA for LNZ100 (aceclidine for presbyopia) under FDA review; PDUFA target Aug 8, 2025; no advisory committee.
Commercial team of 88 sales force hired and trained; launch ready upon FDA approval.
Executed multiple international license deals totaling >$195M potential milestones plus double-digit royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.